Literature DB >> 6105394

Renal clearance of pentavalent antimony (sodium stibogluconate).

P H Rees, M I Keating, P A Kager, W T Hockmeyer.   

Abstract

Kenyan kala-azar is sometimes unresponsive to a standard course of sodium stibogluconate. The renal excretion of sodium stibogluconate was therefore studied in patients with kala azar and in volunteers; both urine and serum levels of sodium stibogluconate were measured. After intravenous injection sodium stibogluconate seemed to be distributed throughout the extracellular fluid and to have a renal clearance similar to that of inulin. At 6 h blood levels had fallen to less than 1% of peak values. After intramuscular injection, peak blood levels were lower and more sustained. However, more than 80% was excreted in the first 6 h, and blood levels fell to around 1% of peak values in 16 h. The dangers of cumulative toxicity may be exaggerated, and restriction of courses of sodium stibogluconate to 30 days or even to 10 days (in the U.S.A.) may not be necessary. If shorter courses are ineffective prolonged and continued courses may be given provided that renal function is assessed and the dosage is adjusted when indicated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105394     DOI: 10.1016/s0140-6736(80)90120-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

2.  Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.

Authors:  C P Thakur; K Kumar; P K Sinha; B N Mishra; A K Pandey
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-10

3.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis.

Authors:  M al Jaser; A el-Yazigi; M Kojan; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Pharmacokinetic modeling as a tool for biological monitoring.

Authors:  P O Droz
Journal:  Int Arch Occup Environ Health       Date:  1993       Impact factor: 3.015

6.  Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers.

Authors:  Laura Vásquez; José V Scorza Dagert; José V Scorza; Nelson Vicuña-Fernández; Yaneira Petit de Peña; Sabrina López; Herminia Bendezú; Elina Rojas; Libia Vásquez; Belén Pérez
Journal:  Curr Ther Res Clin Exp       Date:  2006-05

7.  Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.

Authors:  Keke Fan; Ernest Borden; Taolin Yi
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607

8.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 9.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

10.  Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis.

Authors:  M A Jaser; A el-Yazigi; S L Croft
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.